Compare Newmont Corporation (NEM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Novo Nordisk A/S — how do they compare? Newmont Corporation trades at $117.8 (market cap $121.75B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Novo Nordisk A/S for 116 Days on average.
| NEM | NVO | |
|---|---|---|
Market Cap | $121.75B | $165.31B |
Volume | 5,421,125 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $63.98 |
52-Week Low | $78.63 | $35.29 |
Typical Hold Time | 58 Days | 116 Days |
Enterprise Value | $118.34B | $179.56B |
Dividend Yield | 0.9% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $117.84, up 3.79% over the past 24 hours, with a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has consistently beaten earnings estimates in recent quarters. Revenue grew to $22.67 billion in 2025, with net income reaching $7.09 billion, reflecting a robust profit margin of 31.25%.
The outlook remains positive due to strong cash flow generation and operational improvements, though near-term technical weakness and gold price volatility present risks. Analyst consensus is strongly bullish with a $136.83 price target, indicating potential upside. Key risks include dependence on gold prices and execution of growth projects.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
